Mesalazine rectal foam - Giuliani

Drug Profile

Mesalazine rectal foam - Giuliani

Alternative Names: Asacol foam - Giuliani; Mesalamine rectal foam; SPD 480

Latest Information Update: 15 Aug 2005

Price : $50

At a glance

  • Originator Giuliani
  • Class Aminosalicylic acids; Anti-inflammatories; Irritable bowel syndrome therapies; Small molecules
  • Mechanism of Action Lipoxygenase-cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Marketed Ulcerative colitis

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 28 Jul 2005 Discontinued - Phase-II for Ulcerative colitis in USA (Rectal)
  • 16 Aug 2004 SPD 480 is available for licensing in Japan (http://ww7.investorrelations.co.uk/shirepharma/index.jsp)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top